Crinetics Pharmaceuticals, Inc.
CRNX
$35.20
$0.732.12%
| Weiss Ratings | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.16 | |||
| Price History | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.20% | |||
| 30-Day Total Return | -12.66% | |||
| 60-Day Total Return | -35.57% | |||
| 90-Day Total Return | -37.91% | |||
| Year to Date Total Return | -31.72% | |||
| 1-Year Total Return | -9.58% | |||
| 2-Year Total Return | 104.77% | |||
| 3-Year Total Return | 84.49% | |||
| 5-Year Total Return | 205.56% | |||
| 52-Week High % Change | -44.87% | |||
| 52-Week Low % Change | 8.26% | |||
| Price | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $62.53 | |||
| 52-Week Low Price | $31.84 | |||
| 52-Week Low Price (Date) | Feb 25, 2025 | |||
| 52-Week High Price (Date) | Nov 14, 2024 | |||
| Valuation | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.21B | |||
| Enterprise Value | 1.91B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.71 | |||
| Earnings Per Share Growth | 0.23% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3,050.44 | |||
| Price/Book (Q) | 2.42 | |||
| Enterprise Value/Revenue (TTM) | 1,833.53 | |||
| Price | $35.20 | |||
| Enterprise Value/EBITDA (TTM) | -5.67 | |||
| Enterprise Value/EBIT | -5.62 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 91.49M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 450 6464 | |||
| Address | 6055 Lusk Boulevard San Diego, CA 92121 | |||
| Website | www.crinetics.com | |||
| Country | United States | |||
| Year Founded | 2008 | |||
| Profitability | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -32,613.47% | |||
| Profit Margin | -28,720.69% | |||
| Management Effectiveness | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -20.46% | |||
| Return on Equity | -- | |||
| Income Statement | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.04M | |||
| Total Revenue (TTM) | 1.04M | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | -239.12M | |||
| EBITDA (TTM) | -336.07M | |||
| EBIT (TTM) | -338.85M | |||
| Net Income (TTM) | -298.41M | |||
| Net Income Avl. to Common (TTM) | -298.41M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -34.11% | |||
| EPS Diluted (TTM) | -3.71 | |||
| EPS Diluted Growth (Q YOY) | 1.58% | |||
| Balance Sheet | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.35B | |||
| Cash Per Share (Q) | $14.80 | |||
| Total Current Assets (Q) | 1.38B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.32B | |||
| Current Ratio (Q) | 23.045 | |||
| Book Value Per Share (Q) | $14.26 | |||
| Total Assets (Q) | 1.43B | |||
| Total Current Liabilities (Q) | 59.68M | |||
| Total Debt (Q) | 51.72M | |||
| Total Liabilities (Q) | 109.79M | |||
| Total Common Equity (Q) | 1.32B | |||
| Cash Flow | CRNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -574.82M | |||
| Cash from Financing (TTM) | 1.01B | |||
| Net Change in Cash (TTM) | 209.65M | |||
| Levered Free Cash Flow (TTM) | -136.41M | |||
| Cash from Operations (TTM) | -225.97M | |||
